Platelet and coagulation activation markers in myeloproliferative diseases: Relationships with JAK2 V6I7F status, clonality, and antiphospholipid antibodies

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 8, 2007, Pages 1679-1685

  Robertson, Beverley ^a   Urquhart, C ^b   Ford, I ^b   Townend, J ^b   Watson, H G ^a   Vickers, M A ^a   Greaves, M ^b  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Antiphospholipid; Clonality; Mutation; Myeloproliferative; Platelet; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; BETA2 GLYCOPROTEIN 1 ANTIBODY; BUSULFAN; CARDIOLIPIN ANTIBODY; CLOPIDOGREL; D DIMER; DIPYRIDAMOLE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HYDROXYUREA; JANUS KINASE 2; LUPUS ANTICOAGULANT; PADGEM PROTEIN; PHOSPHOLIPID ANTIBODY; PROTEIN P53; PROTHROMBIN; PROTHROMBIN ANTIBODY; THROMBIN ANTITHROMBIN COMPLEX;

ADULT; AGED; ARTICLE; BIOASSAY; BLOOD CLOTTING; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE MUTATION; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MOLECULAR CLONING; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTIPHOSPHOLIPID; BLOOD COAGULATION; BLOOD PLATELETS; COHORT STUDIES; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; THROMBOSIS;

EID: 34447619693     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02626.x     Document Type: Article

References (24)

1. James C, Ugo V, Casadevall N, Constantinescu SN, Vainchenker W. A JAK2 mutation in myeloproliferative disorders: Pathogenesis and therapeutic and scientific prospects. Trends Mol Med 2005; 11: 546-54.
2. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, Duffy A, Boyd EM, Bench AJ, Scott MA. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: A prospective study. Lancet 2005; 366: 1945-53.
3. James C, Ugo V, Le Couedic J, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, BennaceurGriscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera [Letter]. Nature 2005; 434: 1144-8.
4. Passamonti F, Rumi E, Pietra D, Della Porta MG, Boveri E, Pascutto C, Vanelli L, Arcaini L, Burcheri S, Malcovati L, Lazzarino M, Cazzola M. Relation between JAK2 (V617 F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 2006; 107: 3676-82.
5. Harrison CN, Gale RE, Machin SJ, Linch DC. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications [see comment]. Blood 1999; 93: 417-24.
6. Musolino C, Alonci A, Bellomo G, Tringall G, Spatari G, Quartarone C, Risso V, Calabro L, Bagnato G, Frisina N. Markers of endothelial and platelet status in patients with essential thrombocythaemia and polycythaemia vera. Haematology 2000; 4: 397-402.
7. Falanga A, Marchetti M, Evangelista V, Vignoli A, Licini M, Balicco M, Manarini S, Finazzi G, Cerletti C, Barbui T. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000; 96: 4261-6.
8. Jensen MK, de Nully Brown P, Thorsen S, Hasselbalch HC. Frequent occurrence of anticardiolipin antibodies, Factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disorders. Am J Hematol 2002; 69: 185-91.
9. Harrison CN, Donohoe S, Carr P, Dave M, Mackie I, Machin SJ. Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis. Thromb Haemost 2002; 87: 802-7.
10. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, White H, Zoi C, Loukopoulos D, Terpos E, Vervessou EC, Schultheis B, Emig M, Ernst T, Lengfelder E, Hehlmann R, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162-8.
11. Allen RC, Zoghbi HY, Moseley AB, Rosenblatt HM, Belmont JW. Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. Am J Hum Genet 1992; 51: 1229-39.
12. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 2006; 91: 169-75.
13. Jensen MK, de Nully Brown P, Lund BV, Nielsen OJ, Hasselbalch HC. Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. Eur J Haematol 2001; 66: 143-51.
14. Cassar K, Ford I, Greaves M, Bachoo P, Brittenden J. Randomized clinical trial of the antiplatelet effects of aspirin-clopidogrel combination versus aspirin alone after lower limb angioplasty. Br J Surg 2005; 92: 159-65.
15. Blann AD, Nadar SK, Lip GY. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 2003; 24: 2166-79.
16. Polgar J, Matuskova J, Wagner DD. The P-selectin, tissue factor, coagulation triad. J Thromb Haemost 2005; 3: 1590-6.
17. Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005; 33: 523-30.
18. Vickers MA, McLeod E, Spector TD, Wilson IJ. Assessment of mechanism of acquired skewed X inactivation by analysis of twins. Blood 2001; 97: 1274-81.
19. Campbell PJ, Baxter EJ, Beer PA, Scott LM, Bench AJ, Huntly BJ, Erber WN, Kusec R, Larsen TS, Giraudier S, Le Bousse-Kerdiles MC, Griesshammer M, Reilly JT, Cheung BY, Harrison CN, Green AR. Mutation of JAK2 in the myeloproliferative disorders: Timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 2006; 108: 3548-55.
20. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: A systematic review of the literature [Review, 58 refs]. Blood 2003; 101: 1827-32.
21. Male C, Foulon D, Hoogendoorn H, Vegh P, Silverman E, David M, Mitchell L. Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 2005; 106: 4152-8.
22. Petri M. Epidemiology of the antiphospholipid antibody syndrome [Review, 63 refs]. J Autoimmun 2000; 15: 145-51.
23. Juby AG, Davis P, McElhaney JE, Gravenstein S. Prevalence of selected autoantibodies in different elderly subpopulations. Br J Rheumatol 1994; 33: 1121-4.
24. Levine SR, Brey RL, Tilley BC, Thompson JL, Sacco RL, Sciacca RR, Murphy A, Lu Y, Costigan TM, Rhine C, Levin B, Triplett DA, Mohr JP, APASS I. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291: 576-84.